Verona Pharma plc announced top-line data from its three-day Phase 2 clinical pharmacology trial evaluating the effect of two different doses (1.5 mg and 6.0 mg; twice daily) of nebulized ensifentrine (RPL554) when used on top of an inhaled long-acting muscarinic antagonist/long-acting beta2 agonist (“LAMA/LABA”), tiotropium/olodaterol (Stiolto Respimat). LAMA/LABA therapies are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). Patients already receiving inhaled corticosteroid (“ICS”) therapy were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use. Highlights: Primary endpoint of peak forced expiratory volume in one second (“FEV1”) after morning dose on day 3 of treatment was not met with statistical significance, although the ensifentrine 1.5 mg morning dose improved peak FEV1 by 46 mL, compared to placebo- Improvement in FEV1, compared to placebo, with the 1.5 mg dose was maintained throughout the 24-hour period as measured on day 3; Importantly, peak FEV1 after evening dose on day 3 showed statistically significant improvement, compared to placebo, with both doses, with ensifentrine 1.5 mg showing a 130 mL improvement (p<0.001) and ensifentrine 6.0 mg showing an 81 mL improvement (p=0.002); Ensifentrine at a 1.5 mg dose produced consistent improvements, compared to placebo, in average FEV1 over 12 hours following the morning dose on days 1 to 3, with an improvement of approximately 50 mL on day 3. These improvements were not shown to be statistically significant when adjusted for multiple doses; Reductions in residual volume, compared to placebo, as measured by plethysmography were observed at all time points on day 3 with the 1.5 mg dose.- Statistically significant reductions in mean residual volume were observed 15 minutes following the evening dose on day 3, with ensifentrine 1.5 mg showing a reduction of 259 mL (p<0.002) and ensifentrine 6.0 mg showing a reduction of 142 mL (p<0.036); Ensifentrine 6.0 mg did not result in greater improvement in lung function as compared with the ensifentrine 1.5 mg dose; and Ensifentrine was well tolerated at both doses with an adverse event profile consistent with that observed in prior studies.